JAK2V617F allele burden and thrombosis: A direct comparison in essential thrombocythemia and polycythemia vera

Experimental Hematology

Volumn 37, Issue 9, 2009, Pages 1016-1021

  Carobbio, Alessandra ^a   Finazzi, Guido ^a   Antonioli, Elisabetta ^b   Guglielmelli, Paola ^b   Vannucchi, Alessandro M ^b   Dellacasa, Chiara M ^a   Salmoiraghi, Silvia ^a   Delaini, Federica ^a   Rambaldi, Alessandro ^a   Barbui, Tiziano ^a  

^a OSPEDALI RIUNITI   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BUSULFAN; HYDROXYUREA; JANUS KINASE 2;

ACUTE HEART INFARCTION; ADOLESCENT; ADULT; AGE; AGED; ARTERY THROMBOSIS; ARTICLE; CHILD; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; GENE MUTATION; HUMAN; INCIDENCE; LEUKOCYTE COUNT; LEUKOCYTOSIS; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; POLYCYTHEMIA VERA; PRIORITY JOURNAL; PROGNOSIS; THROMBOSIS; THROMBOTIC THROMBOCYTOPENIC PURPURA; TRANSIENT ISCHEMIC ATTACK; VENOUS THROMBOEMBOLISM;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALLELES; CHILD; FEMALE; HUMANS; JANUS KINASE 2; MALE; MIDDLE AGED; MUTATION, MISSENSE; POLYCYTHEMIA VERA; RISK FACTORS; THROMBOCYTHEMIA, ESSENTIAL; THROMBOSIS;

EID: 68549136745     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exphem.2009.06.006     Document Type: Article

References (21)

1. Baxter E.J., Scott L.M., Campbell P.J., et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365 (2005) 1054-1061
2. Kralovics R., Passamonti F., Buser A.S., et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 352 (2005) 1779-1790
3. Kittur J., Knudson R.A., Lasho T.L., et al. Clinical Correlates of JAK2 V617F Allele Burden in Essential Thrombocythemia. Cancer 109 (2007) 2279-2284
4. Campbell P.J., Scott L.M., Buck G., et al. Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet 366 (2005) 1945-1953
5. Pardanani A., Fridley B.L., Lasho T.L., Gilliland D.G., and Tefferi A. Host genetic variation contributes to phenotypic diversity in myeloproliferative disorders. Blood 111 (2008) 2785-2789
6. Barbui T, Carobbio A, Rambaldi A, Finazzi G. Perspectives on thrombosis in essential thrombocythemia and polycythemia vera: is leukocytosis a causative factor? Blood. 2009 Apr 16. [Epub ahead of print].
7. Vannucchi A.M., Antonioli E., Guglielmelli P., Pardanani A., and Tefferi A. Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal. Leukemia 22 (2008) 1299-1307
8. Carobbio A., Finazzi G., Antonioli E., et al. Thrombocytosis and leukocytosis interaction in vascular complications of essential thrombocythemia. Blood 112 (2008) 3135-3137
9. Carobbio A., Antonioli E., Guglielmelli P., et al. Leukocytosis and risk stratification assessment in essential thrombocythemia. J Clin Oncol 26 (2008) 2732-2736
10. Larsen T.S., Pallisgaard N., Moller M.B., and Hasselbalch H.C. High prevalence of arterial thrombosis in JAK2 mutated essential thrombocythaemia: independence of the V617F allele burden. Hematology 13 (2008) 71-76
11. Dahabreh I.J., Zoi K., Giannouli S., Zoi C., Loukopoulos D., and Vougarelis M. Is JAK2 V617F mutation more than a diagnostic index? A meta-analysis of clinical outcomes in essential thrombocythemia. Leuk Res 33 (2009) 67-73
12. Ziakas P.D. Effect of JAK2 V617F on thrombotic risk in patients with essential thrombocythemia: measuring the uncertain. Haematologica 93 (2008) 1412-1414
13. Lussana F, Caberlon S, Pagani C, Kamphuisen PW, Büller HR, Cattaneo M. Association of V617F Jak2 mutation with the risk of thrombosis among patients with essential thrombocythaemia or idiopathic myelofibrosis: a systematic review. Thromb Res. 2009 Mar 17. [Epub ahead of print].
14. Finazzi G., Rambaldi A., Guerini V., Carobbo A., and Barbui T. Risk of thrombosis in patients with essential thrombocythemia and polycythemia vera according to JAK2 V617F mutation status. Haematologica 92 (2007) 135-136
15. Vannucchi A.M., Antonioli E., Guglielmelli P., et al. Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia. Blood 110 (2007) 840-846
16. Vannucchi A.M., Antonioli E., Guglielmelli P., et al. Prospective identification of high-risk polycythemia vera patients based on JAK2(V617F) allele burden. Leukemia 21 (2007) 1952-1959
17. Barosi G., Bergamaschi G., Marchetti M., et al. JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis. Blood 110 (2007) 4030-4036
18. Gale R.E., Allen A.J., Nash M.J., and Linch D.C. Long-term serial analysis of X-chromosome inactivation patterns and JAK2 V617F mutant levels in patients with essential thrombocythemia show that minor mutant-positive clones can remain stable for many years. Blood 109 (2007) 1241-1243
19. Tefferi A., Strand J.J., Lasho T.L., et al. Bone marrow JAK2V617F allele burden and clinical correlates in polycythemia vera. Leukemia 21 (2007) 2074-2075
20. Theocharides A., Passweg J.R., Medinger M., et al. The allele burden of JAK2 mutations remains stable over several years in patients with myeloproliferative disorders. Haematologica 93 (2008) 1890-1893
21. Carobbio A., Finazzi G., Guerini V., et al. Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors, and Jak2 mutation status. Blood 109 (2008) 2310-2313